CELESTONE® Oral Solution, for oral administration, contains 0.6 mg betamethasone in each 5 mL.
CELESTONE (Betamethasone) is indicated for the following:
Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness.
Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases For the palliative management of leukemias and lymphomas.
Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.
Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
Media Articles Related to Celestone (Betamethasone)
New data shows Leo Pharma A/S investigational psoriasis treatment, Enstilar, provides rapid itch relief for psoriasis patients
Source: Dermatology News From Medical News Today [2015.06.10]
LEO Pharma A/S has announced that new data being presented at the 23rd World Congress of Dermatology shows aerosol foam Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5...
Published Studies Related to Celestone (Betamethasone)
Chinese medicine combined with calcipotriol betamethasone and calcipotriol
ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized
controlled trial. 
BACKGROUND: Psoriasis causes worldwide concern because of its high-prevalence, as
well as its harmful, and incurable characteristics... DISCUSSION: To address the effectual remission of the YXBCM01 granule for PV,
this trial may provide a novel regimen for PV patients if the granule can
decrease relapse rate without more adverse effects.
Calcipotriene plus betamethasone dipropionate topical suspension for the
treatment of mild to moderate psoriasis vulgaris on the body: a randomized,
double-blind, vehicle-controlled trial. 
and limbs... CONCLUSION: The topical suspension containing calcipotriene plus betamethasone
Efficacy of Aloe vera/olive oil cream versus betamethasone cream for chronic skin
lesions following sulfur mustard exposure: a randomized double-blind clinical
0.1% cream... CONCLUSION: A. vera/olive oil cream was at least as effective as betamethasone
Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. [2011.06.01]
BACKGROUND: Corticosteroids are a versatile option for the treatment of mild-to-moderate psoriasis due to their availability in a wide range of potencies and formulations. Occlusion of the corticosteroid is a widely accepted procedure to enhance the penetration of the medication, thereby improving its effectiveness. Betamethasone valerate (BMV) is a moderately potent corticosteroid that is available as a cream, ointment, and lotion. A ready-to-use occlusive dressing, which provides a continuous sustained release of BMV, has been developed for the treatment of psoriasis. OBJECTIVE: To evaluate the efficacy and safety of a new BMV 0.1% plaster compared with a BMV 0.1% cream in patients with mild-to-moderate chronic plaque psoriasis... CONCLUSIONS: BMV 0.1% plaster is more efficacious than BMV 0.1% cream in the treatment of patients with mild-to-moderate chronic plaque psoriasis in a clinical setting resembling daily clinical practice.
Topical betamethasone and hyaluronidase in the treatment of phimosis in boys: a double-blind, randomized, placebo-controlled trial. [2011.05]
PURPOSE: To compare the efficacy of three different formulations containing Betamethasone Valerate versus placebo in the topical treatment of phimosis. As a secondary goal, we compared the outcomes after 30 and 60 days of treatment... CONCLUSIONS: Betamethasone Valerate 0.1%, 0.2% and 0.2% in combination with Hyaluronidase had equally higher results than placebo in the treatment of phimosis in boys from three to ten years-old. Patients initially with partial or no response can reach complete response after 60 days of treatment.
Clinical Trials Related to Celestone (Betamethasone)
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4) [Recruiting]
This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial
comparing three creams in the treatment of impetiginous eczema:
- Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole and gentamicin
- Arm B: Combination of betamethasone diproprionate cream and gentamicin sulfate cream
- Arm C: Betamethasone diproprionate cream
At 7 sites, in Portugal, a total of 207 subjects will be randomized using a 1: 1:1
randomization ratio to receive one of the three possible treatments for a maximum period of
28 days or until 5 days after total remission of the signs and symptoms, but never more than
28 days. Assessments will be made of level of improvement of the target area in each
treatment group, number of days for total remission, and safety profile.
Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section [Recruiting]
This is a randomized, multicenter, double blind, placebo controlled trial of betamethasone
versus a placebo given prior to the mothers at term and near term gestation (>34 and <40
weeks of gestation) who are scheduled to undergo a planned Cesarean section. The study
design is to determine the efficacy and safety of betamethasone in the prevention of
breathing problems commonly seen in this population.
In infants born by elective Cesarean section, it is hypothesized that antenatal
betamethasone treatment will reduce the risk of neonatal intensive care unit (NICU)
admission from 11% to 8% and/or oxygen therapy +/- positive pressure ventilation (PPV) for
>30 minutes from 4. 5% to 2. 5%.
Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA) [Recruiting]
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for
diabetic macular edema.
Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) [Recruiting]
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for
macular edema following branch retinal vein occlusion
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) [Not yet recruiting]
The purpose of this study is to compare the efficacy and safety of LEO 80185 topical
suspension with the active components when used individually as monotherapy in the topical
suspension vehicle (betamethasone dipropionate in the topical suspension vehicle,
calcipotriol in the topical suspension vehicle) and with the topical suspension vehicle
alone in the treatment of psoriasis vulgaris on the non-scalp regions of the body (trunk
and/or limbs) in a large phase 3 study. This comparison will ensure a more informed
assessment of the benefit/risk ratio of LEO 80185 topical suspension while also establishing
the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of the body
(trunk and/or limbs).
Reports of Suspected Celestone (Betamethasone) Side Effects
Maternal Exposure During Pregnancy (4),
Injection Site Necrosis (3),
Product Quality Issue (3),
Rash Maculo-Papular (3),
Body Temperature Increased (2),
Dyspnoea Exertional (2),
Caesarean Section (2), more >>
Page last updated: 2015-06-10